Chen S, et al. - Researchers investigated the impact of baseline lipid-lowering therapy (LLT) in patients undergoing revascularization for left main (LM) coronary artery disease (CAD) by assessing outcomes for 1,905 patients with LMCAD randomly allocated to percutaneous coronary intervention (PCI) vs coronary artery bypass grafting (CABG) by whether or not they were taking lipid-lowering therapy (LLT) at baseline in the EXCEL trial. Patients with and without LLT at baseline had comparable 3-year major adverse event rates after PCI vs CABG for LMCAD. However, patients with baseline LLT, but not those without baseline LLT, underwent revascularization more commonly after PCI vs CABG during follow-up.